RxDoctor Payments Data

Candace Sanders, MD

Neurology · Nashville, TNNPI 1205218419

Payments from drug & device makers

$1,811in general payments, 2019–2025

Across 34 payments — averaging $53.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuropace, Inc.$794
  • UCB, Inc.$168
  • Jazz Pharmaceuticals Inc.$164
  • Immedica Pharma US, Inc.$148
  • Lilly USA, LLC$136
  • SK Life Science, Inc.$131
  • plus $271 from 7 others

What the payments were for

  • Travel & lodging$31217%
  • Food & beverage$1,50083%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,811 in reported general payments places this provider in the 40th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$60,981
Medicare patients
243
Services billed
1,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam49$103,376
KeppraLevetiracetam14$69,465
XcopriCenobamate41$59,865
Emgality PenGalcanezumab-Gnlm59$39,434
QuliptaAtogepant15$23,875
Nurtec OdtRimegepant Sulfate14$21,308
UbrelvyUbrogepant11$17,931
Lacosamide40$10,640
Levetiracetam155$6,625
Clobazam49$4,970
Lamotrigine ErLamotrigine24$4,147
Desvenlafaxine Succinate ErDesvenlafaxine Succinate34$3,381
Lamotrigine131$2,837
Oxcarbazepine27$2,441
Gabapentin94$2,390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$168$103,37649 claims
SK Life Science, Inc.Xcopri$131$59,86541 claims
AbbVieQulipta, Ubrelvy$58$41,80526 claims
PfizerNurtec Odt$65$21,30814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 361 neurology providers in Tennessee.

Other neurology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →